海南海药:接受申万宏源证券资产管理有限公司等投资者调研
Group 1 - The core viewpoint of the article is that Hainan Haiyao (SZ 000566) has conducted an investor survey, providing insights into its business structure and financial performance [1] - As of the first half of 2025, Hainan Haiyao's revenue composition is as follows: 78.45% from pharmaceuticals, 18.6% from medical service fees, and 2.95% from other businesses [1] - The current market capitalization of Hainan Haiyao is 7.7 billion yuan [1]